[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR20030021298A - The composition of immune enhancer and intestinal regulator for animal - Google Patents

The composition of immune enhancer and intestinal regulator for animal Download PDF

Info

Publication number
KR20030021298A
KR20030021298A KR1020010054338A KR20010054338A KR20030021298A KR 20030021298 A KR20030021298 A KR 20030021298A KR 1020010054338 A KR1020010054338 A KR 1020010054338A KR 20010054338 A KR20010054338 A KR 20010054338A KR 20030021298 A KR20030021298 A KR 20030021298A
Authority
KR
South Korea
Prior art keywords
animal
wood vinegar
composition
weight
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020010054338A
Other languages
Korean (ko)
Inventor
최형규
Original Assignee
최형규
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 최형규 filed Critical 최형규
Priority to KR1020010054338A priority Critical patent/KR20030021298A/en
Publication of KR20030021298A publication Critical patent/KR20030021298A/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 아스코르빈산 처리 안정화 목초액과 틴달화 유산균 배양물을 주성분으로 하는 동물용 면역증진 및 정장용 조성물에 관한 것으로서, 동물에 급여시 동물의 면역력을 증강시켜 각종 질병으로 인한 피해를 감소시켜주며, 장을 건강하게 유지하고 사료효율을 개선시켜 동물의 생산성을 향상시켜 주는 동물용 면역증진 및 정장용 조성물에 관한 것이다.The present invention relates to an animal immunostimulating and formal composition comprising ascorbic acid-treated stabilizing wood vinegar and chitin and lactic acid bacteria culture as a main component, to increase the immunity of the animal when fed to reduce the damage caused by various diseases, The present invention relates to an animal immunostimulating and dressing composition for improving the productivity of the animal by keeping the intestine healthy and improving feed efficiency.

Description

동물용 면역증진 및 정장용 조성물{THE COMPOSITION OF IMMUNE ENHANCER AND INTESTINAL REGULATOR FOR ANIMAL}Immunity Enhancement and Formal Composition for Animals {THE COMPOSITION OF IMMUNE ENHANCER AND INTESTINAL REGULATOR FOR ANIMAL}

본 발명은 아스코르빈산 처리 안정화 목초액과 틴달화 유산균 배양물을 주성분으로 하는 동물용 면역증진 및 정장용 조성물에 관한 것으로서, 좀더 상세하게는 대한민국 특허출원 10-2001-0050219호(아스코르빈산 처리 안정화 목초액 및 이를 함유하는 소독약 조성물)에서 개시하고 있는 아스코르빈산 처리 안정화 목초액과 틴달화 유산균 배양물(tyndallized lactic acid bacteria culture)을 주성분으로 하여 가축의 면역증진, 항병력 강화 및 소화기관의 정장을 통하여 질병의 발생을 예방하고 질병 발생시 회복을 빠르게 하여 피해를 감소시키기 위한 목적으로 사용하는 동물용 면역증진 및 정장용 복합조성물에 관한 것이다.The present invention relates to an animal immunostimulating and formal composition comprising ascorbic acid-treated stabilizing wood vinegar and chitin and lactic acid bacteria culture as a main component, more specifically Korean Patent Application No. 10-2001-0050219 (ascorbic acid-treated stabilizing wood vinegar) And ascorbic acid-treated stabilizing wood vinegar and tyndallized lactic acid bacteria culture, which are disclosed in the disinfectant composition containing the same, as a main ingredient, to enhance the disease of the disease by enhancing the immune system of animals, strengthening the history of the disease, and suiting the digestive organs. The present invention relates to a composite composition for animal immunostimulation and formal use for the purpose of preventing the occurrence and speeding up recovery in the event of a disease, to reduce the damage.

목초액은 나무가 탄화할 때 발생되는 연기(재래식 숯가마의 경우 배연온도 80℃∼150℃, 기계식의 경우 연기채취온도 150℃ 이하)를 냉각시켜 정제과정을 거치지 않고 얻은 액체를 조목초액(crude wood vinegar)이라 하며 조목초액을 적어도 2∼3일간 정치하여 2층 또는 3층으로 분리한후 2층으로 분리된 경우는 상층부, 3층으로 분리된 경우는 중간층의 적갈색 수용성액을 3개월 이상 숙성(ageing)후흡착(adsorption), 여과(filtration) 등의 탈타르처리를 하여 얻은 액체나, 조목초액을 필터 등으로 여과하거나 증류 등의 방법으로 목초액 중에 불안정한 성분을 제거시켜 획득한 맑고 투명한 적갈색, 담적갈색 및 담황색 수용성액체를 정제 목초액(refined wood vinegar)이라 한다(임업연구원 고시 제1999-35호 제6조).Wood vinegar is a crude wood vinegar (crude wood vinegar) obtained by cooling the smoke produced when wood carbonizes (combustion temperature 80 ℃ ~ 150 ℃ for conventional charcoal kiln, below 150 ℃ for smoke collection temperature for mechanical). The crude wood vinegar is allowed to stand for at least 2 to 3 days to separate into 2 or 3 layers, and then, when separated into 2 layers, the reddish brown aqueous solution of the middle layer is aged for 3 months or more (ageing). Clear and clear reddish brown and light reddish brown obtained by removing unstable components from wood vinegar by filtering the liquid or crude wood vinegar with a filter or by distillation such as after adsorption and filtration. And the pale yellow water-soluble liquid is called refined wood vinegar (Article 6, Notification No. 1999-35, Forestry Research Institute).

목초액에는 200여종 이상의 유기산 성분과 10여종 이상의 미네랄과 비타민이 함유되어 있어 유해한 활성산소(free radical)를 제거하는 SOD(superoxide dismutase)기능이 탁월하여 세포내의 이물질을 제거하고 세포의 호흡회로를 정상화하여 세포를 건강하게 유지시켜 줌으로써 유익한 작용을 하는 물질로서 식품 및 의약품에 이미 널리 사용되고 있다.Wood vinegar contains more than 200 organic acids and more than 10 kinds of minerals and vitamins. It has excellent SOD (superoxide dismutase) function that removes harmful free radicals, removes foreign substances in cells and normalizes the respiratory circuit of cells. It is already widely used in foods and medicines as a substance that acts beneficially by keeping cells healthy.

최근 축산물의 소비량이 증가되면서 축산물의 안전성에 대한 소비자들의 요구가 과거 어느 때보다도 높아지고 있으며, 또한 세계 각국은 자국의 축산물 생산자와 소비자를 동시에 보호하기 위해 총칼 없는 전쟁인 동물 질병 방역을 위한 검역전쟁을 벌이고 있다. 질병을 예방하기 위한 첨단기술의 백신(예방약)개발에도 불구하고 매년 질병의 발생은 증가되고 있는 추세이며, 생산자인 양축농가에서는 질병의 예방과 치료를 위하여 동물용 의약품인 합성항균제(chemotherapeutics)나 항생물질(antibiotics)을 사용하고 있으나, 이들의 과용과 오ㆍ남용에 따른 문제점이 가축의 장내 세균과 병원성 세균의 내성화로 인해 치료효과의 둔화를 가져오게 하고, 나아가 더 많은 항생제의 사용을 초래하고 있다. 더욱이 계란이나 우유 및 고기에 이들 항균성 물질이 이행, 잔류됨으로써 공중보건상에 미치는 영향과 내성화된 세균이 축산식품을 통하여 사람의 장관내로 들어가면 장내 세균에 내성인자를전달하여 사람의 질병치료효과를 둔화시킬 가능성이 높다는 문제점들이 제기되고 있다.With the recent increase in the consumption of livestock products, consumers' demands for the safety of livestock products have risen more than ever before, and countries around the world are fighting the quarantine war for animal disease prevention, a total knifeless war, to simultaneously protect their livestock producers and consumers. I'm working. Despite the development of state-of-the-art vaccines (prevention drugs) to prevent diseases, the incidence of diseases is increasing every year, and producers of livestock farmers use synthetic antimicrobial agents (chemotherapeutics) or antibiotics for the prevention and treatment of diseases. Although antibiotics are used, the problems caused by their overuse and misuse can lead to a slowing of the therapeutic effect due to the resistance of intestinal and pathogenic bacteria in livestock, and further the use of more antibiotics. have. Furthermore, the effects of these antimicrobial substances on eggs, milk and meat are transferred to and remain in public health, and when resistant bacteria enter the human intestine through livestock foods, they deliver resistance factors to the intestinal bacteria to treat human diseases. Problems are raised that are likely to slow down.

금년도에 농림부에서 발표한 자료에 의하면 도축검사중 해체검사과정에서 질병에 의한 병변확인이나 기생충 검사로 인한 부적합율은 한우 5.99%, 돼지 2.33%, 닭 0.39%로 보고하고 있다. 병변에 의한 부적합내역중 소화기질병에 의한 부적합율은 한우에서 50.1%, 돼지에서 26.0%, 닭에서 26.2%로 호흡기질병, 순환기질병 및 생식기질병에 비하여 상대적으로 높은 점유율을 보이고 있다.According to the data released by the Ministry of Agriculture and Forestry this year, the inconsistency rate due to disease identification or parasite inspection during the dismantling test during slaughter test is reported as 5.99% for Korean cattle, 2.33% for pigs and 0.39% for chickens. The proportion of inadequate disease caused by digestive diseases was 50.1% in Korean cattle, 26.0% in pigs, and 26.2% in chickens, which was relatively higher than respiratory diseases, circulatory diseases, and reproductive diseases.

동물의 소화기질병은 세균이나 바이러스 및 기생충 같은 병원체와 환경이나 영양, 스트레스 등과 같은 비전염성 요인들이 단독 또는 복합적으로 작용하여 발생되며 주로 설사를 동반하게 된다. 최근들어 집약적인 대규모 생산방식과 고밀도 사육, 동물의 유전적인 생산능력의 지속적인 향상, 약제의 과다사용에 따른 장내 미생물종의 변화, 사료 원료중 영양소 불균형의 심화 및 원료곡물의 생산과 저장을 위한 화학처리제의 사용증가는 동물에 스트레스를 가중시켜 소화기관이나 면역기능의 위축을 초래하여 질병에 대한 저항력을 악화시키고 있다.Digestive diseases of animals are caused by pathogens such as bacteria, viruses, and parasites, and non-communicable factors such as environment, nutrition, and stress, alone or in combination, and are mainly accompanied by diarrhea. In recent years, intensive large-scale production, high-density breeding, continuous improvement of genetic production capacity of animals, changes in intestinal microflora due to overuse of drugs, deepening nutrient imbalances in feed ingredients, and chemicals for production and storage of raw grains Increasing use of treatments adds stress to animals, leading to atrophy of the digestive system and immune function, making them more resistant to disease.

셀리(Selye)는 동물이 스트레스를 받게 되면 흉선(thymus) 및 림프기관(lymphatic organ)이 위축되어 면역기능과 생체방어기능이 저하되고, 소화불량 또는 위나 십이지장 궤양등 소화기 질병이 증가하며, 부신(Adrenal)의 증대를 가져온다고 보고하였으며 메이어(Meyer)는 스트레스를 받을시 상기도감염증이 4배나 높았다고 하였다.Selye, when an animal is stressed, contracts the thymus and lymphatic organs, which decreases immune and biological defenses, increases digestive diseases such as indigestion or stomach or duodenal ulcers, Reported an increase in adrenality, and Meyer reported four times higher upper respiratory tract infections when stressed.

특히 감보로병(Infectoius bursal disease), 마렉병(Marek's disease), 세망내피증(Reticuloendotheliosis), 저혈당증(Hypoglysemia), 흉막폐렴(Actinobacillus pleuropneuomonia), 닭전염성 빈혈증, 레오바이러스 감염증(Reo virus disease), 곰팡이독소 중독증(Mycotoxicosis)같은 면역파괴 질병의 발생증가 및 확산은 동물의 심각한 면역기능 저하를 초래하여 질병에 대한 감수성을 크게 증대시키고 있다.Specifically, Infectoius bursal disease, Marek's disease, Reticuloendotheliosis, Hypoglycemia, Actinobacillus pleuropneuomonia, Infectious chicken anemia, Reo virus disease, Fungus The increasing incidence and proliferation of immunodestructive diseases, such as toxin poisoning (Mycotoxicosis), leads to severely impaired immune function in animals, greatly increasing their susceptibility to disease.

따라서 동물에 대한 면역력을 향상시키고 소화기관의 기능유지 및 개선을 위하여 생균제(probiotics)가 널리 이용되고 있다. 생균제는 장내 미생물총의 균형을 유지하고 개선시켜 숙주동물에 유익한 작용을 하는 살아있는 미생물 제제로서 각종 질병에 대한 항병력을 증가시키고 설사발생을 감소시키며 혈청내 콜레스테롤 함량감소 및 백혈구에의한 식균작용(phagocytosis)을 증강시킨다(Gerald W. Tannock, 1999, Probiotics a critical review, p1,Horizen scientific press).Therefore, probiotics are widely used for improving immunity to animals and maintaining and improving the function of the digestive organs. Probiotics are living microbial agents that have a beneficial effect on the host animal by balancing and improving the intestinal microflora, increasing anti-microbial resistance against various diseases, reducing diarrhea, reducing serum cholesterol levels and phagocytosis by leukocytes. (Gerald W. Tannock, 1999, Probiotics a critical review, p1, Horison scientific press).

이소라우리(Isolauri)는 생균제가 동물의 소장상피에 바이러스나 세균이 침입시 이뮤노글로부린에이(IgA) 반응을 유발하게 하는 항염증 사이토카인(anti-inflammatory cytokins)과 함께 식균작용에 영향을 미친다고 하였다. 카일라등(Kaila et al.)은 유산균을 섭취시 설사하는 동안 장내에서 이뮤노글로부린 에이(IgA)의 분비를 증가시켜 설사증을 경감시키고 면역력을 증가시킨다고 하였으며, 듀피등(Duffy et al.)은 유산균을 동물에 급여시 면역증강 작용에 의하여 로타바이러스(Rota virus)설사증을 완화시켰다고 하였다.Isolauri suggests that probiotics affect phagocytosis along with anti-inflammatory cytokins that cause immunoglobulin-A (IgA) reactions when viruses or bacteria enter the animal's small intestine epithelium. It was. Kaila et al. Reported that diarrhea and diarrhea were increased by increasing the secretion of immunoglobulin A (IgA) in the intestine during diarrhea when ingesting lactic acid bacteria. Duffy et al. Rota virus diarrhea was relieved by the immune boosting effect when fed to animals.

그러나 이러한 생균제는, 동물의 소화관이 시험관과 다르기 때문에 장관에 영구하게 정착하는 것을 나타내는 증거가 불분명하고 지속적인 효과가 필요하면 연속적으로 투여하여야 하는 문제점이 있다(Fuller,1992, 축산의연구 제46권 제1호, p44). 또한 주위환경 조건에 따라 기대하는 효과가 미흡하고 안정성에 문제가 있어 유통과정이나 사료의 가공처리 특히, 펠렛 같은 사료의 경우 열처리 과정중 균수가 감소하는 등 품질상에 문제점이 있으며, 가축의 성장단계에 따른 효과의 불균일등 문제점을 가지고 있다(이인호,2000,Direct-fed microbials 이론의 기술경영적 접근, p17-19, 신우일터축산정보쎈타).However, because these probiotics differ from the test tube of animals, there is a problem in that the evidence indicating permanent settling in the intestine should be administered continuously if the evidence indicating permanent settling is unclear and a continuous effect is required (Fuller, 1992, Livestock Research Vol. 46, No. 46). 1, p44). In addition, the expected effect is insufficient depending on the environmental conditions and there is a problem in stability, so there is a problem in the quality of the distribution process or the processing of feed, especially in the case of feed such as pellets, the number of bacteria decreases during the heat treatment process. Effects such as non-uniformity of effects (In-Ho Lee, 2000, Technical Management Approach to Direct-fed Microbials Theory, p17-19, Shinwoo Plant Livestock Information Center).

최근 들어 위에서 설명한 생균제의 안정성(stability)의 문제점을 해결하기 위하여 사균제의 일종인 틴달화 유산균 배양물이 가축의 면역 증진 및 설사예방 목적으로 사용되고 있으나, 생균제에 비하여 직접적이고 단기적인 효과가 떨어지고 가격이 비싸 축산분야에 널리 활용되지 못하고 있는 실정이다.Recently, in order to solve the problem of the stability of the probiotics described above, the culture of the bactericidal agent, tindal lactic acid bacteria, has been used for the purpose of enhancing the immunity and diarrhea prevention of livestock. Expensive livestock is not widely used in the situation.

본 발명의 목적은 상기와 같은 문제점을 해결하기 위해 광범위한 기초조사를 바탕으로 연구한 결과, 틴달화 유산균 배양물에 아스코르빈산 처리 안정화 목초액을 복합 처방하여 동물에 급여시 기존의 틴달화 유산균 배양물 제제에 비하여 정장효과가 뛰어나고 탁월한 면역증진효과가 있는 동물용 면역증진 및 정장용 조성물을 제공하는 것이다.The purpose of the present invention is to study the problem based on a wide range of basic investigations to solve the above problems, as a result of the formulation of ascorbic acid-treated stabilizing wood vinegar complex in the culture of tindal lactic acid bacteria, the existing cultures of tindal lactic acid bacteria when fed to animals It is to provide a composition for immunity boosting and dressing for animals that is superior to the formulation and has an excellent immune enhancing effect.

본 발명은 아스코르빈산 처리 안정화 목초액 2∼30중량%와 틴달화 유산균 배양물 2∼20중량%로 이루어진 동물용 면역증진 및 정장용 조성물에 관한 것이다.The present invention relates to an animal immunostimulating and formal composition comprising 2 to 30% by weight of ascorbic acid-treated stabilized wood vinegar and 2 to 20% by weight of tindal lactobacillus culture.

이하, 본 발명을 상세하게 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail.

본 발명에서 사용되는 아스코르빈산 처리 안정화 목초액(이하 안정화 목초액이라 함)은 대한민국 특허출원 102001-000000호에서 개시하고 있는 안정화 목초액으로서 통상의 목초액 제조방법에 따라 제조된 목초액을 숙성전 단계에서 목초액의 1∼20중량%의 아스코르빈산을 첨가, 용해시켜 실온에서 6개월간 숙성 시킨후 200(mesh) 필터로 여과하여 획득된 것이다. 아스코르빈산은 목초액을 안정화(stabilization) 시키고 활성화(activation) 시키기 위해서 사용하였으며 목초액 숙성시 목초액의 1∼20중량%를 첨가함으로서 목초액의 안정성(stability)과 효능(efficacy)을 증강시킬 수 있다. 이는 아스코르빈산이 전자수송체계(electron transport system)에 관여하여 산소의 산화(oxidation)능력을 비활성화시켜 목초액의 산화를 방지하며 아스코르빈산이 목초액속에 잔류해 있는 중금속들과 결합함으로써 목초액의 순도에 영향을 미치기 때문인 것으로 생각된다.Ascorbic acid-treated stabilizing wood vinegar used in the present invention (hereinafter referred to as stabilizing wood vinegar) is a stabilizing wood vinegar disclosed in the Republic of Korea Patent Application No. 102001-000000 of the wood vinegar prepared according to the conventional wood vinegar preparation method in the pre-aging step 1-20% by weight of ascorbic acid was added and dissolved, aged at room temperature for 6 months, and then obtained by filtration with a 200 (mesh) filter. Ascorbic acid was used to stabilize and activate wood vinegar, and it is possible to enhance the stability and efficacy of wood vinegar by adding 1-20% by weight of wood vinegar. This prevents the oxidation of wood vinegar by inactivating oxygen oxidation ability by ascorbic acid in the electron transport system, and ascorbic acid combines with heavy metals remaining in wood vinegar to improve the purity of wood vinegar. It seems to be because it affects.

상기 아스코르빈산 처리 안정화 목초액은 2∼30중량% 사용되는 것이 바람직한데, 2중량% 미만인 경우에는 면역증진 및 설사예방효과가 미흡하고, 30중량%를 초과할 경우에는 효과는 우수하지만 조성물의 안정성이 저하되고 사용상에 불편이 따르는 단점이 있다. 즉, 본 발명에 사용되는 안정화 목초액은 액상으로 되어있어서, 동물용 면역증진 및 정장용 조성물 제조시 100∼200메쉬의 제올라이트에 흡착시켜 사용하여야 하기 때문에 안정화 목초액의 함량이 높아지게 되면, 조성물중의 수분함량이 증가되어 제품이 변질될 우려가 있으며 사료에 첨가시 혼합시간이 많이 소요하게 된다.The ascorbic acid-treated stabilizing wood vinegar is preferably used 2 to 30% by weight, less than 2% by weight of the immune boosting and diarrhea prevention effect is insufficient, when more than 30% by weight is excellent but the composition stability There is a disadvantage that this is lowered and inconvenience in use. That is, the stabilized wood vinegar used in the present invention is in a liquid phase, and thus, when the content of the stabilized wood vinegar is increased, the content of the stabilized wood vinegar should be used by adsorbing it to 100 to 200 mesh zeolites in the preparation of animal immunostimulation and formal dressings. This increases the risk of product deterioration, and when added to the feed it takes a lot of mixing time.

본 발명에서 사용되는 틴달화 유산균 배양물은 FDA에 등재되어 있는GRAS(Generally Regarded As Safe)미생물에 포함되는 유산균(lactic acid bacteria)주를 발효과정중 간헐열처리(tyndallization)를 수회 반복하여 최종적으로 획득되는 사균제 배양물로서, 우수한 정장작용과 약간의 국소면역증진효과가 입증되어 설사예방 및 치료제로서 사람 및 동물에 널리 사용되고 있다. 틴달화 열처리 공법에 의해 제조된 사균제에는 병원체의 장점막 부착을 차단하고 체외로 배출시키는 역할을 하는 사균체와 사균체가 장상피세포의 수용체 부위에 강력하게 부착할 수 있도록 도와주는 내열성 결합인자와 장국소면역을 활성화 시켜주는 면역증강인자, 틴달화과정에서 생성되는 정균성물질 및 유기산 및 비타민 B군 같은 유산균 증식물질이 함유되어 설사, 연변등 장내 소화기 질병을 예방한다. 이처럼 사균제 배양물은 병원체가 장점막에 부착하지 못하고 체외로 배출되게 하는 차단 및 축출작용과 병원체보다 훨씬더 강력한 장점막 부착에 의해서 장내에서 병원체가 작용할 수 없게 하는 경쟁적 배제원리에 의해서 설사를 예방하여줌으로 기존의 항생제나 생균제와는 전혀 다른 신개념 설사 예방제로서 내성이 없고 열과 산에 안정하여 사료공장이나 동물사육자가 안심하고 사용할 수 있다(현대양돈 통권 153호, p117-119, 주식회사 현축).The culture of tindal lactic acid bacteria used in the present invention is finally obtained by repeating the lactic acid bacteria strain contained in the GRAS (Generally Regarded As Safe) microorganism listed in the FDA several times during the fermentation process. As a fungicide culture, it has been proved to have an excellent intestinal action and a slight local immune boosting effect, and is widely used in humans and animals as a diarrhea prevention and treatment agent. The bactericidal agent produced by the tindal heat treatment method includes a heat-resistant binding factor that helps to strongly adhere to the receptor site of the intestinal epithelial cell, which is responsible for blocking the adhesion of the pathogens of the pathogen and discharging it into the body. It contains immune enhancing factors that activate gut topical immunity, bacteriostatic substances produced during the process of tindalization, and lactic acid bacteria proliferative substances such as organic acids and vitamin B groups to prevent intestinal digestive diseases such as diarrhea and stool. This fungal culture prevents diarrhea by blocking and eviction, which prevents pathogens from attaching to the intestinal mucosa and excreting it in vitro, and competitive exclusion principles that prevent pathogens from working in the intestine by attaching a much stronger mesenteric membrane than the pathogen. As a new concept diarrhea preventive agent that is completely different from existing antibiotics and probiotics, it is not resistant and stable to heat and acid, so that it can be used safely by feed mills and animal breeders (Hyundai Swine No. 153, p117-119, Hyun-Sung Co., Ltd.).

상기 틴달화 유산균 배양물의 함량은 2∼20중량%인 것이 바람직한데, 2중량% 미만인 경우에는 면역증진 및 설사예방 효과가 미흡하고, 20중량%를 초과하는 경우에는 효과는 우수하지만 안정화 목초액과의 적정비율을 유지하기 위한 조성물의 생산 자체가 어려우며 비경제적인 문제가 있어 바람직하지 못하다.The content of the tindal lactic acid bacteria culture is preferably 2 to 20% by weight, but less than 2% by weight of the effect of immunopromoting and diarrhea prevention is insufficient, in the case of more than 20% by weight with stabilized wood vinegar Production of the composition itself to maintain the proper ratio is difficult and uneconomical problems are undesirable.

상기 틴달화 유산균 배양물은 틴달화 락토바실러스 아시도필루스배양물(tyndallized Lactobacillus acidophilus culture; 이하 TLAC라 함)을 사용하는 것이 바람직하다.It is preferable to use the tydallized Lactobacillus acidophilus culture (hereinafter, referred to as TLAC) as the chintalized lactic acid bacteria culture.

본 발명의 조성물은 동물의 사료에 첨가, 혼합하여 투여하는 것이 권장되며 동물사료에 0.04∼0.3%의 비율로 혼합하여 투여하는 것이 바람직하다. 사료에의 첨가비율은 동물의 성장단계, 건강상태 및 질병상태에 따라 변화시킬 수 있다.It is recommended that the composition of the present invention is added to the animal feed, mixed and administered, and mixed and administered to the animal feed at a rate of 0.04 to 0.3%. The rate of addition to the feed can vary depending on the growth stage, health and disease state of the animal.

본 발명은 하기 실시예 및 비교예에 의하여 보다 구체적으로 이해될 수 있고, 하기의 실시예는 본 발명을 예시하기 위한 것에 지나지 않으며 본 발명의 보호범위를 제한하고자 하는 것은 아니다.The present invention can be understood in more detail by the following examples and comparative examples, the following examples are only for illustrating the present invention and are not intended to limit the protection scope of the present invention.

실시예 및 비교예Examples and Comparative Examples

<실시예 1><Example 1>

대한민국 특허 출원번호 10-2001-0050219호에 기술된 아스코르빈산이 5중량% 처리된 안정화 목초액을 제올라이트(왕표제올라이트, 왕표화학 제품)에 1:4(안정화 목초액:제올라이트)비율로 흡착하여 건조시킨 안정화 목초액 분말 40g(안정화 목초액으로서 1중량%)과 10중량%의 TLAC(ZOOLOC concentrated, Lacteol사 제품, France)를 5분간 혼합한후, 여기에 100중량%가 되도록 탄산칼슘을 가하여 5분간 혼합하여 동물용 면역증진 및 정장제를 제조하였다.Stabilized wood vinegar treated with 5% by weight of ascorbic acid described in Korean Patent Application No. 10-2001-0050219 was adsorbed to zeolite (Kangje Zeolite, Wangje Chemical) at a ratio of 1: 4 (stabilized wood vinegar: zeolite) and dried. 40 g of stabilized wood vinegar powder (1% by weight as stabilized wood vinegar) and 10% by weight of TLAC (ZOOLOC concentrated, manufactured by Lacteol, France) were mixed for 5 minutes, and then calcium carbonate was added to 100% by weight and mixed for 5 minutes. Animal immunostimulation and formal preparations were prepared.

<실시예 2><Example 2>

안정화 목초액을 5중량% 투입한 것을 제외하고는 실시예 1과 동일하게 하여 동물용 면역증진 및 정장제를 제조하였다.Except for adding 5% by weight of stabilized wood vinegar in the same manner as in Example 1 was prepared for animal immunostimulation and formal preparation.

<실시예 3><Example 3>

안정화 목초액을 10중량% 투입한 것을 제외하고는 실시예 1과 동일하게 하여 동물용 면역증진 및 정장제를 제조하였다.Except that 10% by weight of stabilized wood vinegar was prepared in the same manner as in Example 1 to prepare an animal immune booster and formal preparation.

<실시예 4><Example 4>

안정화 목초액을 20중량% 투입한 것을 제외하고는 실시예 1과 동일하게 하여 동물용 면역증진 및 정장제를 제조하였다.Except for adding 20% by weight of stabilized wood vinegar in the same manner as in Example 1 was prepared for animal immunostimulation and formal preparation.

<비교예 1>Comparative Example 1

10중량%의 TLAC에 100중량%가 되도록 탄산칼슘을 가하여 7분간 혼합하여 동물용 면역증진 및 정장제를 제조하였다.Calcium carbonate was added to 10% by weight of TLAC to 100% by weight, and mixed for 7 minutes to prepare an animal immune booster and suit.

<실험예 1>Experimental Example 1

자돈에 대한 설사 예방효과 비교시험Comparative test for the prevention of diarrhea on piglets

1. 실험방법1. Experiment Method

어미젖을 뗀 이유자돈을 24마리씩 5개군으로 나누어 분류하고 14일간 농협에서 생산한 이유자돈 사료(가루사료)에 실시예 1, 2, 3, 4 및 비교예 1을 각각 0.1%씩 첨가하여 급여하고 투여 중단후 1주까지의 설사 발생마리수와 분변내 대장균수를 측정하였다. 각군별 대장균수 측정은 군별로 각각의 자돈이 배설한 분변 1그람씩을 무균적으로 정확하게 채취하여 희석액으로 희석하고 DHL배지(영연화학사)를 사용하여 37℃에서 48시간 동안 배양한 후 대장균수를 측정하였다.The mothers weaned the weaning piglets into 24 groups of 24 and divided them into five groups, and fed 14, 1, 2, 3, 4 and Comparative Example 1 to the weaning pig feed (powdered feed) produced by the Agricultural Cooperatives for 14 days, respectively. The number of diarrhea and the number of coliform bacteria in the feces were measured up to 1 week later. E. coli counts for each group were aseptically collected 1 gram of fecal excreted by each pig in each group, diluted with diluent and incubated for 48 hours at 37 ℃ using a DHL medium (Youngyeon Chemical Co., Ltd.) Measured.

2. 실험결과2. Experimental Results

비교예 1급여군은 설사 발생 자돈수가 2두로서 8.3%의 설사 발생율을 보였으며, 안정화 목초액이 1중량% 함유된 실시예 1 급여군 역시 설사 발생 자돈수가 2두로서 비교예에 비하여 개선되지 못하였다. 그러나 안정화 목초액이 5중량% 함유된 실시예 2 급여군은 설사 발생율이 4.2%이었으며, 실시예 3, 4 급여군은 설사가 발생되지 않아 안정화 목초액의 복합처방시 설사 예방효과가 크게 개선됨이 입증되었다.Comparative Example 1 group showed diarrhea incidence with 2 heads of diarrhea and 8.3%, and Example 1 feed group containing 1% by weight of stabilized wood vinegar also did not improve as 2 heads of diarrhea occurred. It was. However, Example 2 feed group containing 5% by weight of stabilized wood vinegar was 4.2% diarrhea incidence, diarrhea incidence of Example 3, 4 pay group was proved to significantly improve the effectiveness of diarrhea prevention when combined prescription of stabilized wood vinegar solution .

분변내 대장균수는 비교예 1 급여군의 경우 급여후 14일차에 91.1%가 감소되었고, 급여종료후 7일차에는 다시 급격하게 증가하여 급여전에 비하여 54%의 감소를 보였다. 실시예 1을 급여한 돈분에서는 급여 14일차에 93.3%의 감소를 보였고 급여종료 7일차에는 58%가 감소되어 비교예 1에 비해서는 대장균 감소효과가 인정되었으나 만족할만한 수준이 아니었다. 그러나 실시예 2, 3, 4 급여군의 돈분내에서는 급여 14일차에 시험 개시전에 비하여 대장균수가 각각 98.2%, 99.1%, 99.4%가 감소되었고 급여종료후 7일차에도 각각 96.5%, 97.1%, 98.5%가 감소되어 정장효과가 우수함이 입증되었다. 그 결과는 다음 표 1, 2와 같다.In fecal coliforms, 91.1% of the control group of the comparative example 1 was decreased on the 14th day after the end of the salary, and increased rapidly again on the 7th day after the end of the salary. In the pig meal fed Example 1, 93.3% of the salary was reduced on the 14th day and 58% of the end of the salary was reduced, compared to that of Comparative Example 1, but the effect of reducing E. coli was not satisfactory. However, E. coli counts were reduced by 98.2%, 99.1%, and 99.4%, respectively, on day 14 after salary, and 96.5%, 97.1%, and 98.5 on day 7, respectively. The percentage was reduced and proved to be excellent suiting effect. The results are shown in Tables 1 and 2 below.

각군별 설사발생두수 및 발생율Diarrhea Incidence and Incidence Rate 실시예 1급여군Example 1 salary group 실시예 2급여군Example 2 salary group 실시예 3급여군Example 3 pay group 실시예 4급여군Example 4 Salary Group 비교예 1급여군Comparative Example 1 salary group 시험마리수Trials 24두24 heads 24두24 heads 24두24 heads 24두24 heads 24두24 heads 설사마리수Diarrhea 22 1두1 head 0두0 heads 0두0 heads 2두2 heads 설사발생율Diarrhea Rate 8.3%8.3% 4.2%4.2% 0%0% 0%0% 8.3%8.3%

각군별 대장균 균총의 평균치Average value of E. coli flora in each group 투여 1일전1 day before administration 투여 7일차Day 7 Dosing 투여 14일차Day 14 Dosing 중단후 7일차7 days after suspension 실시예1 급여군Example 1 Salary Group 1.6 ×105 1.6 × 10 5 5.6 ×104 5.6 × 10 4 1.1 ×104 1.1 × 10 4 6.7 ×104 6.7 × 10 4 실시예2 급여군Example 2 Salary Group 2.3 ×105 2.3 × 10 5 6.1 ×104 6.1 × 10 4 4.1 ×103 4.1 × 10 3 8.1 ×103 8.1 × 10 3 실시예3 급여군Example 3 Salary Group 1.8 ×105 1.8 × 10 5 2.7 ×104 2.7 × 10 4 1.6 ×103 1.6 × 10 3 5.2 ×103 5.2 × 10 3 실시예4 급여군Example 4 Salary Group 2.1 ×105 2.1 × 10 5 2.5 ×104 2.5 × 10 4 1.2 ×103 1.2 × 10 3 3.1 ×103 3.1 × 10 3 비교예1 급여군Comparative Example 1 Salary Group 1.0 ×105 1.0 × 10 5 3.9 ×104 3.9 × 10 4 8.9 ×103 8.9 × 10 3 4.6 ×104 4.6 × 10 4

<실험예 2>닭의 체액성 면역 증가효과 Experimental Example 2 Humoral Immune Increasing Effect of Chicken

1. 실험 방법1. Experiment Method

1) 실험동물1) Experimental Animal

갈색 산란계 병아리 75수를 각각 15수씩 실시예 1, 2, 3, 4 및 비교예 1 급여군등 5개군으로 나누어 본 실험을 실시하였다.This experiment was carried out by dividing 75 number of brown laying chicks into 15 groups, each of 15 groups including Example 1, 2, 3, 4 and Comparative Example 1 salary group.

2) 실험방법2) Experiment Method

① 투여방법 : 모든 병아리에 28일령에 Newcastle disease 바이러스 B1 생독백신을 수당 106EID50씩 점안접종 하였으며 21일령부터 35일령까지 14일간 각 계군별로 실시예 1, 2, 3을 및 비교예 1 조성물을 각각 수당 1일 60mg씩 급여하였다.① Administration method: All chicks were inoculated with Newcastle disease virus B1 live poison vaccine at 28 days of age by 106EID50 of allowance, and each of the groups was treated with compositions of Examples 1, 2, 3 and Comparative Example 1 for 14 days from 21 days to 35 days of age. 60 mg daily.

② HI 항체가 측정 : 백신접종 2주후인 42일령에 각수수마다 익하 정맥에서 혈액을 2∼3cc 채취한 다음 혈청을 분리하여 마이크로플레이트(microplate)판을 이용하여 212까지 희석하여 뉴캣슬 바이러스에 대한 HI 항체가를 측정하였다.② Measurement of HI antibody: 2 ~ 3cc of blood was collected from subcutaneous vein at 42 days of age, 2 weeks after vaccination, and serum was separated and diluted to 212 using microplate plate. Antibody titer was measured.

2. 실험결과2. Experimental Results

실험동물의 체액성 면역증진효과를 알아보기 위하여 백신접종 2주후 뉴캣슬 바이러스 B1에 대한 HI 항체가를 분석한 결과, 비교예 1 급여군이 58.49이었으며, 실시예 1 투여구 역시 58.49로서 항체가가 증가되지 않았으나 실시예 2 급여군은 73.52로서 비교예 1 급여군에 비하여 25.7%가 증가되었고, 실시예 3, 4 급여군은각각 106.15 및 111.43으로서 비교예 1에 비하여 각각 81.5%, 90.5%가 증가하였다. 그 결과는 다음 표 3와 같다.In order to investigate the humoral immune-promoting effect of experimental animals, HI antibody titer of Newcastle virus B1 was analyzed two weeks after vaccination, and the comparative group 1 was 58.49 and the administration of Example 1 was also 58.49. However, in Example 2, the pay group was 73.52, which was 25.7% higher than that of Comparative Example 1, and in Examples 3 and 4, respectively, 106.15 and 111.43 were increased by 81.5% and 90.5%, respectively, compared to Comparative Example 1. . The results are shown in Table 3 below.

뉴캣슬 바이러스 B1의 HI항체역가HI Antibody Titer of Newcastle Virus B1 구분division 시험두수Test head lig2titer별 마리수 분포lig 2 titer distribution 평균Average 십진법수정치Decimal Correction 1One 22 33 44 55 66 77 88 99 1010 1111 1212 실시예1급여군Example 1 Salary Group 1515 -- -- -- 22 44 44 44 1One -- -- -- -- 5.875.87 58.4958.49 실시예2급여군Example 2 Salary 1515 -- -- -- -- 44 66 33 22 -- -- -- -- 6.206.20 73.5273.52 실시예3급여군Example 3 Salary 1515 -- -- -- -- 22 55 44 33 1One -- -- -- 6.736.73 106.15106.15 실시예4급여군Example 4 Salary Group 1515 -- -- -- 1One -- 55 44 55 -- -- -- -- 6.806.80 111.43111.43 비교예1급여군Comparative Example 1 salary group 1515 -- -- -- 1One 55 55 33 1One -- -- -- -- 5.875.87 58.4958.49

이상에서 볼 수 있는 바와 같이, 본 발명에 의해 제조된 동물용 면역증짐 및 정장용 조성물은 안정화 목초액을 틴달화 유산균 배양물에 적용함으로써 틴달화 유산균 배양물 단독 급여시보다 면역증강 및 정장효과에 있어 월등한 상승효과를 얻을 수 있다.As can be seen from the above, the animal immunosuppression and formal dressing composition prepared by the present invention is superior to the immune boosting and formal effect by applying stabilizing wood vinegar to the culture of tindal lactobacillus culture alone. A synergistic effect can be obtained.

Claims (3)

통상의 목초액에 아스코르빈산을 1∼20중량% 첨가, 용해시켜 실온에서 6개월간 숙성시킨 후 필터로 여과하여 얻어진 아스코르빈산 처리 안정화 목초액과 틴달화 유산균 배양물을 주성분으로 하여 제조되는 것을 특징으로 하는 동물용 면역증진 및 정장용 조성물.1 to 20% by weight of ascorbic acid is added to a conventional wood vinegar, dissolved, aged at room temperature for 6 months, and then filtered using a filter. Animal immunostimulating and formal composition for. 제 1항에 있어서, 아스코르빈산 처리 안정화 목초액은 2∼30중량%이고, 틴달화 유산균 배양물은 2∼20중량%인 것을 특징으로 하는 동물용 면역증진 및 정장용 조성물.According to claim 1, Ascorbic acid-treated stabilizing wood vinegar is 2 to 30% by weight, chitin and lactic acid bacteria culture is characterized in that 2-20% by weight of the composition for animal immunostimulation and formal use. 제 1항 또는 제 2항에 있어서, 상기 틴달화 유산균 배양물은 틴달화 락토바실러스 아시도필루스 배양물인 것을 특징으로 하는 동물용 면역증진 및 정장용 조성물.According to claim 1 or 2, wherein the chitin is lactic acid bacteria culture animal immunostimulating and formal composition, characterized in that the chitin is Lactobacillus asidophilus culture.
KR1020010054338A 2001-09-05 2001-09-05 The composition of immune enhancer and intestinal regulator for animal Ceased KR20030021298A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020010054338A KR20030021298A (en) 2001-09-05 2001-09-05 The composition of immune enhancer and intestinal regulator for animal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020010054338A KR20030021298A (en) 2001-09-05 2001-09-05 The composition of immune enhancer and intestinal regulator for animal

Publications (1)

Publication Number Publication Date
KR20030021298A true KR20030021298A (en) 2003-03-15

Family

ID=27722530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020010054338A Ceased KR20030021298A (en) 2001-09-05 2001-09-05 The composition of immune enhancer and intestinal regulator for animal

Country Status (1)

Country Link
KR (1) KR20030021298A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060102942A (en) * 2005-03-25 2006-09-28 (주)이엘티사이언스 Composite composition for activating a probiotic for animals and its manufacturing method
US7571737B2 (en) 2006-08-01 2009-08-11 Jeongwoo Jang Joint structure of fold type tent frame
WO2012060579A3 (en) * 2010-11-04 2012-08-02 주식회사 쎌바이오텍 Dead lactobacillus biomass for antimicrobial use and a production method therefor
WO2013094846A1 (en) * 2011-12-19 2013-06-27 Kim Dae Hyun Pharmaceutical composition comprising dead cells of lactobacillus acidophilus lb strain for treating or preventing allergic disease
WO2017080696A1 (en) * 2015-11-10 2017-05-18 Delphi Beteiligungsgesellschaft mbH Novel hygiene article

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62269647A (en) * 1986-05-17 1987-11-24 Fuyuo Fukaya Feed
US5171575A (en) * 1987-01-19 1992-12-15 Nisshin Flour Milling Co., Ltd. Process for preventing diarrhea in animals
JPH0748217A (en) * 1993-08-04 1995-02-21 Matsukaade:Kk Antibacterial agent
KR980000101A (en) * 1998-01-20 1998-03-30 조건식 Animal feed additives using chitosan
JP2000316486A (en) * 1999-05-14 2000-11-21 Sadao Amishima Feed additive for poultry farming use
KR20030016580A (en) * 2001-08-21 2003-03-03 최형규 The stabilized wood vinegar treated with ascorbic acid and the composition of disinfectant including the stabilized wood vinegar

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62269647A (en) * 1986-05-17 1987-11-24 Fuyuo Fukaya Feed
US5171575A (en) * 1987-01-19 1992-12-15 Nisshin Flour Milling Co., Ltd. Process for preventing diarrhea in animals
JPH0748217A (en) * 1993-08-04 1995-02-21 Matsukaade:Kk Antibacterial agent
KR980000101A (en) * 1998-01-20 1998-03-30 조건식 Animal feed additives using chitosan
JP2000316486A (en) * 1999-05-14 2000-11-21 Sadao Amishima Feed additive for poultry farming use
KR20030016580A (en) * 2001-08-21 2003-03-03 최형규 The stabilized wood vinegar treated with ascorbic acid and the composition of disinfectant including the stabilized wood vinegar

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060102942A (en) * 2005-03-25 2006-09-28 (주)이엘티사이언스 Composite composition for activating a probiotic for animals and its manufacturing method
US7571737B2 (en) 2006-08-01 2009-08-11 Jeongwoo Jang Joint structure of fold type tent frame
WO2012060579A3 (en) * 2010-11-04 2012-08-02 주식회사 쎌바이오텍 Dead lactobacillus biomass for antimicrobial use and a production method therefor
CN102725397A (en) * 2010-11-04 2012-10-10 细胞生物技术公司 Dead lactobacillus biomass for antimicrobial use and a production method therefor
KR101369219B1 (en) * 2010-11-04 2014-03-03 정명준 Antibacterial tyndalized lactic acid bacteria and preparing method thereof
WO2013094846A1 (en) * 2011-12-19 2013-06-27 Kim Dae Hyun Pharmaceutical composition comprising dead cells of lactobacillus acidophilus lb strain for treating or preventing allergic disease
US9421231B2 (en) 2011-12-19 2016-08-23 Dae Hyun Kim Pharmaceutical composition including dead cells of Lactobacillus acidophilus LB to treat or prevent allergic disease
US9744198B2 (en) 2011-12-19 2017-08-29 Dae Hyun Kim Pharmaceutical composition including dead cells of Lactobacillus acidophilus LB to treat or prevent allergic disease
WO2017080696A1 (en) * 2015-11-10 2017-05-18 Delphi Beteiligungsgesellschaft mbH Novel hygiene article

Similar Documents

Publication Publication Date Title
Ahmadifar et al. Cornelian cherry (Cornus mas L.) fruit extract improves growth performance, disease resistance, and serum immune-and antioxidant-related gene expression of common carp (Cyprinus carpio)
CN101664421B (en) A traditional Chinese medicine biological preparation for preventing and treating livestock and poultry diarrhea, its preparation method and feed
JP2003501080A (en) Bacterial strains, processed plant extracts and probiotic compositions for use in humans and animals
EA017656B1 (en) Composition for prevention and treatment of pig dysentery
KR100474945B1 (en) Composition for reducing somatic cell and preventing or treating mastitis of dairy cattle
KR101803069B1 (en) Composition for improving livestock immunity comprising probiotics as effective component
CN110692863A (en) Plant extract feed additive for improving liver and intestine protecting capability of tilapia
KR100871837B1 (en) Bacterial Culture Having Effects of Suppressing Dermatitis Development and Accelerating Skin Wound Healing, and Product Using The Same
Nofouzi et al. Beneficial effects of killed Tsukamurella inchonensis on rainbow trout (Oncorhynchus mykiss) growth, intestinal histology, immunological, and biochemical parameters
WO2014175509A1 (en) Composition for preventing and relieving calf diarrhea and manufacturing method therefor
KR950011733B1 (en) Disease resistance ration and feed additive for cattles and swines
CN114052116B (en) Probiotic plant extract compound biological agent and preparation method and application thereof
KR100923226B1 (en) Antimicrobial-enhanced Lactic Acid Bacteria Preparation and its Manufacturing Method
KR102283415B1 (en) Product, making method and composites for Antimicrobial
CN110201142A (en) A kind of compound preparation and preparation method thereof for preventing and treating hen salpingitis
KR102197664B1 (en) Product, making method and composites for Antibiosis
KR20030021298A (en) The composition of immune enhancer and intestinal regulator for animal
CN110959773B (en) Feed additive and feed for preventing streptococcicosis of tilapia mossambica, and preparation method and application of feed additive and feed
CN102614294B (en) Compound amoxicillin suspension injection and preparation method thereof
US5741494A (en) Immunopotentiative and infection-protective agent containing bacillus and egg white
WO2015184109A1 (en) Methods of treating diarrhea in adult non-human animals
KR20010068226A (en) composition containing chitosan oligo saccharide and aminoethyl sulfonic acid for use as fodder and drinking water additives
CN113057261A (en) Acid preparation composition for improving production performance of meat pigeons, preparation method and application
CN114177232A (en) Extraction method of tea polyphenol extract, extracted tea polyphenol extract and application thereof
CN101797374A (en) Compound minocycline hydrochloride soluble powder for treating respiratory diseases of poultry

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20010905

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040128

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20040807

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I